Shares of IQVIA Holdings were higher after the company cleared earnings and revenue projections for the second quarter and delivered a major jump in backlog and bookings.

The stock was up 8.3% at $230.99 in premarket trading. Shares had been slowly recovering from a major tumble in February and are now $15 away from a 52-week high.

The company, a major research organization and top provider of biopharmaceutical development and commercial outsourcing services, said revenue climbed 8.7% to $4.37 billion, topping estimates for $4.3 billion from analysts polled by FactSet.

IQVIA posted adjusted earnings of $3.15 a share, beating analyst forecasts for $3.03 a share.

Net new bookings were up 19% from the year prior and the company ended the quarter with a backlog of $34.2 billion, with expectations to convert about $9.2 billion of that into revenue in the next year.